Analysis Of Income And Expense [Abstract]

Captor Therapeutics S.A. - Filing #6064395

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Interest income	—	1 044 PLN	—	—	—	—	—	—	—	—	—	3 083 PLN	—	—	—	—	—	—
Revenue	—	15 825 PLN	—	—	—	—	—	—	—	—	—	13 201 PLN	—	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	43 900 PLN	—	—	—	—	—	—	—	—	—	70 885 PLN	—	—	—	—	—	—
Other finance income	—	0 PLN	—	—	—	—	—	—	—	—	—	0 PLN	—	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	5,000 PLN	—	—	—	—	—	—	—	—	—	1,000 PLN	—	—	—	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 PLN	38 431 PLN	0 PLN	0 PLN	0 PLN	5,000 PLN	0 PLN	38 426 PLN	38 431 PLN	0 PLN	1,000 PLN	70 585 PLN	0 PLN	0 PLN	70 584 PLN	0 PLN	70 585 PLN	0 PLN
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	38 431 PLN	—	—	—	—	—	—	—	—	—	70 585 PLN	—	—	—	—	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	0 PLN	—	—	—	—	—	—	—	—	—	0 PLN	—	—	—	—	—	—